Phase III, Open-Label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Subcutaneous Amivantamab Administered via On Body Delivery System in Patients with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy PALOMA-3.

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05388669

Study #:
STUDY00149774

Start Date:
Apr 14, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05388669

View Complete Trial Details & Eligibility at ClinicalTrials.gov